Vyome Holdings, Inc.

Healthcare · Biotechnology · United States

Last price 1.75 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 12.28M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company’s lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5′-monophosphate dehydrogenase enzyme...